Abstract
Introduction: Infections caused by respiratory syncytial virus (RSV) occur in most children by 2 years of age. Although symptoms are often absent or mild, RSV is the most frequent cause of bronchiolitis and pneumonia in infants and young children and an important source of morbidity, mortality, and financial burden worldwide. Prophylaxis using Palivizumab is recommended for infants with risk factors for severe RSV infection (e.g., lung disease or prematurity), with a maximum of 5 monthly doses during the RSV season. However, the epidemiology of RSV differs widely across latitudes and meteorological conditions. In temperate climates, RSV activity is maximal during winter, with biannual cycles in some countries, but not in others. As the monthly administration of Palivizumab needs to be timed according to local circulation patterns of the virus, we investigated the seasonal pattern of RSV in Belgium.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
